Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
56.3M
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
7.58M
-
Shares change
-
+2.35M
-
Total reported value, excl. options
-
$12.5M
-
Value change
-
+$3.95M
-
Put/Call ratio
-
0
-
Number of buys
-
16
-
Number of sells
-
-14
-
Price
-
$1.65
Significant Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) as of Q2 2025
48 filings reported holding QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.58M shares
of 56.3M outstanding shares and own 13.47% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (2.53M shares), VANGUARD GROUP INC (1.45M shares), IEQ CAPITAL, LLC (439K shares), GEODE CAPITAL MANAGEMENT, LLC (397K shares), RENAISSANCE TECHNOLOGIES LLC (380K shares), BlackRock, Inc. (336K shares), HighTower Advisors, LLC (309K shares), Alphabet Inc. (189K shares), Rockefeller Capital Management L.P. (170K shares), and Shay Capital LLC (150K shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.